The 741-patient, Phase III UNITI-1 study met its primary endpoint with Stelara treatment groups demonstrating significantly higher rates of clinical response at week six when compared with the placebo group.
Here are four points:
1. At week six, 34 percent of patients receiving Stelara achieved clinical response, compared with 22 percent of patients taking a placebo.
2. At week eight, 34 percent achieved clinical response, compared with 20 percent of patients in the control arm.
3. In addition, 16 percent of patients taking the drug achieved clinical remission at week eight, compared with 7 percent on placebo.
4. Adverse events, serious adverse events and infections were reported in similar proportions across Stelara and placebo treatment groups.
More articles on GI & endoscopy:
College Heights Endoscopy Center welcomes Pennsylvania Rep. Charlie Dent: 5 key notes
GI physician leader to know: Dr. Farshid Rahbar of Los Angeles Integrative Gastroenterology & Nutrition
8 things to know about gastroenterologist salary
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.